1. Pink Sheet
  2. >>Market Access
  3. >>PBMs

PBMs, FTC and IRA: Experts Tackle Pharma’s Tough Acronyms At BioFuture Conference

 
• By Jessica Merrill

Some of the industry’s biggest challenges, and potential solutions, were hot topics at the BioFuture conference in New York.

A member of Congress said during the conference that he was sympathetic to industry efforts to change the time before drugs and biologics are subject to price negotiations. (Shutterstock)

New drug pricing policies implemented as part of the Inflation Reduction Act (IRA), the Federal Trade Commission (FTC)’s actions on mergers and acquisitions, and the thorny role of pharmacy benefit managers (PBMs) in the US drug reimbursement system were some of the topics that came up during the BioFuture conference in New York City on 27 October.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from PBMs

PBMs Must Prepare For Revival Of Drug Price Transparency Requirements

 
• By Jill Drachenberg

Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.

Is Optum Rx Payment Remodel To Favor Generics A Peace Offering For US FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Study Shows ‘Insurer-PBMs’ Dominate Medicare Part D, Steer Patients to Their Pharmacies

 
• By Jinghong Chen

An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.

PBM Reform Legislation Do-Over Will Need Bipartisan Help Amid Partisan Budget Battle

 
• By Cathy Kelly

The leader of the House Energy and Commerce Health Subcommittee has a plan for passing pharmacy benefit manager reforms, but Democrats are skeptical.

More from Elections

Pink Sheet Podcast: Kennedy’s Assurances To Gain HHS Nod, US FDA Coms Freeze Continues Thawing

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss what pushed a crucial Senate Finance Committee swing vote to support Robert F. Kennedy Jr. as HHS Secretary and the FDA slowly expanding its communications with the public amid the Trump Administration freeze.

US FDA’s Absence Raises Concerns About International Standards Development

 
• By Elizabeth Orr

The FDA's recent communications freeze has blocked participation in international standards development groups, which could impact the alignment of US and international requirements.

US FDA And The ‘Move Fast And Break Things’ Government

 
• By Michael McCaughan

The Trump transition so far has all the hallmarks of the tech industry’s favorite management slogan, but that might not work well for biopharma companies if the FDA is one of the agencies that gets broken.